Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
J Med Virol ; 92(2): 129-138, 2020 02.
Article in English | MEDLINE | ID: mdl-31502669

ABSTRACT

The number of new and improved human viral vaccines licensed in recent years contrasts sharply with what could be termed the golden era (1955-1990) when vaccines against polio-, measles, mumps, rubella, and hepatitis B viruses first became available. Here, we attempt to explain why vaccines, mainly against viruses other than human immunodeficiency virus and hepatitis C virus, are still unavailable. They include human herpesviruses other than varicella-zoster virus, respiratory syncytial and most other respiratory, enteric and arthropod-borne viruses. Improved oral poliovirus vaccines are also urgently required. Their unavailability is attributable to regulatory/economic factors and the properties of individual viruses, but also to an absence of relevant animal models and ethical problems for the conduct of clinical of trials in pediatric and other critical populations. All are portents of likely difficulties for the licensing of effective vaccines against emerging pathogens, such as avian influenza, Ebola, and Zika viruses.


Subject(s)
Viral Vaccines/economics , Viral Vaccines/immunology , Viral Vaccines/supply & distribution , Virus Diseases/prevention & control , Animals , Antibodies, Viral , Chickenpox Vaccine/immunology , Clinical Trials as Topic/ethics , Dengue Vaccines/immunology , Disease Models, Animal , Ebola Vaccines/immunology , Humans , Influenza Vaccines/immunology , Measles-Mumps-Rubella Vaccine/immunology , Poliovirus Vaccine, Oral/immunology , Rotavirus Vaccines/immunology , Zika Virus/immunology
2.
J Virol Methods ; 252: 8-14, 2018 02.
Article in English | MEDLINE | ID: mdl-29102516

ABSTRACT

Inhibition of viral replication by icIgA antibodies has only been observed with in vitro studies using epithelial cell lines in transwell cultures. This effect appears to involve an interaction between polymeric immunoglobulin A (pIgA) and viral particles within an intracellular compartment, since IgA is transported across polarized cells. Polyclonal guinea pig antisera against purified influenza A virus and mouse antisera prepared against Influenza A/H3N2 hemagglutinin (HA0) cleavage loop peptides, were used in confocal fluorescence microscopy to show specific staining of wild-type influenza H1N1 and H3N2 viruses in clinical specimens. The HA0 cleavage loop peptides used for intranasal immunization of mice were designed and synthesized from specific conserved regions of influenza A/H1N1 & A/H3N2 viruses. Anti-human secretory IgA antibodies were used to show co-localisation of influenza A virus and icIgA. The results showed specific immunofluorescent staining of influenza A/H3N2 (X31) (HA0 uncleaved)-infected MDCK cells and the presence of icIgA in respiratory exudate cells of infected patients. Both results confirm specific co-localisation and suggest interaction between influenza A virus and icIgA in patients' respiratory exudate cells. Importantly, antisera to the mouse anti-HA0 cleavage site were specific for wild-type virus in clinical specimens, indicating that the conserved region of HA0 was present in the uncleaved form. Similar staining and colocalization patterns between icIgA and virus were observed with polyclonal guinea pig antisera against influenza A virus. These are the first observations of co-localization of influenza A virus and intracellular IgA in clinical specimens. Role of icIgA: This report shows the co-localization of influenza A virus HA0 and icIgA antibodies in respiratory exudate cells of patients who were culture and viral RNA positive, suggesting that icIgA directed against the conserved HA0 site may have a privileged and unique opportunity to act on immature virus and thus prevent HA0 cleavage, maturation and subsequent cycles of viral replication. The precise mechanism by which icIgA mediates intracellular viral neutralization remains to be fully elucidated. SIGNIFICANCE: The above findings in clinical specimens would contribute strongly to our understanding of the mechanisms and kinetics of icIgA neutralization in relation to viral entry and early replication steps of mucosal viral infections. A rapid, objective and sensitive assay - by ex vivo enumeration of respiratory epithelial cells that have co-localized influenza virus and icIgA - would contribute to further mucosal immunity studies and inform the design of more effective vaccines against influenza and other viral infections transmitted via the mucosal route e.g. respiratory syncytial virus, rotavirus.


Subject(s)
Antibodies, Viral/immunology , Cytoplasm/immunology , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Immunoglobulin A/immunology , Influenza A virus/immunology , Nasopharynx/virology , Animals , Dogs , Fluorescent Antibody Technique , Guinea Pigs , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Madin Darby Canine Kidney Cells , Mice , Nasopharynx/cytology , Virus Replication
3.
Vaccine ; 33(43): 5786-5793, 2015 Oct 26.
Article in English | MEDLINE | ID: mdl-26407922

ABSTRACT

Seasonal inactivated influenza vaccines are usually trivalent or quadrivalent and are prepared from accredited seed viruses. Yields of influenza A seed viruses can be enhanced by gene reassortment with high-yielding donor strains, but similar approaches for influenza B seed viruses have been largely unsuccessful. For vaccine manufacture influenza B seed viruses are usually adapted for high-growth by serial passage. Influenza B antigen yields so obtained are often unpredictable and selection of influenza B seed viruses by this method can be a rate-limiting step in seasonal influenza vaccine manufacture. We recently have shown that selection of stable cold-adapted mutants from seasonal epidemic influenza B viruses is associated with improved growth. In this study, specific mutations were identified that were responsible for growth enhancement as a consequence of adaptation to growth at lower temperatures. Molecular analysis revealed that the following mutations in the HA, NP and NA genes are required for enhanced viral growth: G156/N160 in the HA, E253, G375 in the NP and T146 in the NA genes. These results demonstrate that the growth of seasonal influenza B viruses can be optimized or improved significantly by specific gene modifications.


Subject(s)
Adaptation, Biological , Cold Temperature , Influenza B virus/growth & development , Influenza B virus/radiation effects , Point Mutation , Animals , Dogs , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Influenza B virus/genetics , Madin Darby Canine Kidney Cells , Mutation, Missense , Neuraminidase/genetics , Nucleocapsid Proteins , Viral Core Proteins/genetics , Viral Proteins/genetics , Virus Cultivation/methods
4.
Vaccine ; 32(21): 2474-9, 2014 May 01.
Article in English | MEDLINE | ID: mdl-24631096

ABSTRACT

Gene reassortment has proved useful in improving yields of influenza A antigens of egg-based inactivated vaccines, but similar approaches have been difficult with influenza B antigens. Current regulations for influenza vaccine seed viruses limit the number of egg passages and as a result resultant yields from influenza B vaccine seed viruses are frequently inconsistent. Therefore, reliable approaches to enhance yields of influenza B vaccine seed viruses are required for efficient vaccine manufacture. In the present study three stable cold-adapted (ca) mutants, caF, caM and caB derived from seasonal epidemic strains, B/Florida/4/2006, B/Malaysia/2506/2004 and B/Brisbane/60/2008 were prepared, which produced high hemagglutinin antigen yields and also increased viral yields of reassortants possessing the desired 6:2 gene constellation. The results demonstrate that consistent improvements in yields of influenza B viruses can be obtained by cold adaptation following extended passage. Taken together, the three ca viruses were shown to have potential as donor viruses for the preparation of high-yielding influenza B vaccine viruses by reassortment.


Subject(s)
Adaptation, Physiological , Cold Temperature , Influenza B virus/growth & development , Influenza Vaccines , Animals , Chickens , Dogs , Hemagglutination Inhibition Tests , Hemagglutinin Glycoproteins, Influenza Virus/isolation & purification , Influenza B virus/genetics , Madin Darby Canine Kidney Cells , Ovum/virology , Reassortant Viruses/genetics , Reassortant Viruses/growth & development , Serial Passage , Virus Cultivation
5.
Avian Pathol ; 41(2): 161-76, 2012.
Article in English | MEDLINE | ID: mdl-22515535

ABSTRACT

We report the pathotyping of six Australian isolates of Marek's disease virus-1 (MDV1) isolated between 1992 and 2004 and association of virulence with meq gene polymorphism. Unvaccinated and herpesvirus of turkeys (HVT)-vaccinated specific pathogen free chickens were challenged at day 5 with 500 plaque forming units of Marek's disease virus. The isolates induced gross Marek's disease lesions in 53 to 94% of unvaccinated chickens, and HVT induced a protective index ranging from 38 to 100% by 56 days post challenge. This experiment provides evidence that current Australian isolates of MDV1 vary significantly in pathogenicity. However, there was no clear evidence that the most virulent recent isolates were more pathogenic than isolates from the 1980s or that any of the isolates belong to the highest pathotype category of very virulent plus. Evidence is presented that virulence can be predicted by measurements taken as early as 13 days post challenge. The meq gene sequences of five of the isolates used in the experiment were determined. When compared with the very virulent US isolate Md5, there was a 177 base-pair insertion and distinct point mutations in each of the five isolates. There were no individual mutations in the meq sequences that correlated with levels of virulence. However, amino acid alignment of the five Australian and 14 international isolates revealed that the number of repeat sequences of four prolines (PPPP repeats) in the meq gene (overall range 2 to 8) was strongly associated with virulence across all isolates, with the most pathogenic isolates having the fewest number of repeats. The results suggest that the presence of the 177 base-pair insertion alone is not an indicator of attenuation. Rather, the number of PPPP repeats, independent of the presence of the insertion, is a better indicator of pathogenicity.


Subject(s)
Chickens , Herpesvirus 2, Gallid/pathogenicity , Marek Disease/virology , Oncogene Proteins, Viral/genetics , Polymorphism, Genetic/genetics , Poultry Diseases/virology , Amino Acid Sequence , Animals , Australia , Base Sequence , Herpesvirus 2, Gallid/genetics , Marek Disease/mortality , Marek Disease/pathology , Molecular Sequence Data , Poultry Diseases/mortality , Poultry Diseases/pathology , Repetitive Sequences, Amino Acid/genetics , Sequence Alignment , Sequence Analysis, DNA , Virulence
6.
J Med Virol ; 84(1): 170-81, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22028179

ABSTRACT

The therapeutic activity of arbidol was investigated against representatives of seven different virus families. Its 50% median effective concentration (EC(50) ) was 0.22-11.8 µg/ml (0.41-22 nM). Therapeutic indices of 91 were obtained for type 1 poliovirus and 1.9-8.5 for influenza A and B, human paramyxo-3, avian infectious bronchitis-, and Marek's disease viruses. Arbidol was more inhibitory for influenza A/Aichi/2/68 (H3N2) virus than rimantadine or amantadine (EC(50) 10 vs. >15 and >31.6 µg/ml); greater inhibition occurred when end-points were expressed as TCID(50) s. For respiratory syncytial virus (RSV), a reduction in plaque size but not number was observed. However, when the drug was added to infected cultures (≥5 µg/ml), a 3-log reduction in titer occurred. Arbidol did not inhibit directly influenza A/Aichi/2/68 hemagglutinin (HA) or neuraminidase (NA) activity, but inhibition of fusion between the viral envelope and chicken red blood cells occurred when added at 0.1 µg/ml prior to infection. Arbidol induced changes to viral mRNA synthesis of the PB2, PA, NP, NA, and NS genes in MDCK cultures infected with influenza A/PR/8/34. There was no indirect evidence of enhancement of interferon-α by arbidol following infection with A/Aichi/2/68. Arbidol neither reduced lung viral titers nor caused a significant reduction of lung consolidation in BALB/c mice after administration by the oral and intraperitoneal (i.p.) routes and intranasal challenge with influenza A/Aichi/2/68. A small reduction in lung consolidation, but not viral titer, occurred after i.p. administration and subsequent challenge with RSV. The results indicate the potential of arbidol as a broad-spectrum respiratory antiviral drug.


Subject(s)
Antiviral Agents/pharmacology , Indoles/pharmacology , Respiratory Tract Infections/virology , Viruses/drug effects , Animals , Antiviral Agents/administration & dosage , Cell Line , Disease Models, Animal , Humans , Indoles/administration & dosage , Lung/pathology , Lung/virology , Male , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests/methods , Orthomyxoviridae Infections/drug therapy , Viral Load , Viral Plaque Assay , Viruses/isolation & purification
7.
J Virol Methods ; 162(1-2): 14-21, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19628008

ABSTRACT

Current methods for the accurate diagnosis of influenza based on culture of the virus or PCR are highly sensitive and specific but require specialised laboratory facilities and highly trained personnel and, in the case of viral culture, can take up to 14 days to obtain a definitive result. In this study, a quartz crystal microbalance-based immunosensor (QCM) has been developed and its potential evaluated for the rapid and sensitive detection of both influenza A and B viruses in laboratory-cultured preparations and clinical samples. The effective limit for detection by QCM for stock preparations of both A/PR/8/34 and B/Lee/40 viruses was 1 x 10(4) pfu/mL, associated with observed frequency shifts of 30 (+/-5) and 37 (+/-6.5) Hz, respectively. Conjugation of 13 nm gold nanoparticles to the detecting antibody improved the mass sensitivity of the immunosensor, resulting in a 10-fold increase in sensitivity and a detection limit of 1 x 10(3) pfu/mL for both preparations, with resulting frequency shifts of 102 (+/-11) and 115 (+/-5) Hz, respectively. Detection of virus in nasal washes with this technique was achieved by overnight passage in MDCK cultures prior to analysis. A comparison of results obtained from 67 clinical samples using existing RT-PCR, shell vial, cell culture and ELISA methods showed that QCM techniques were comparable in sensitivity and specificity to cell culture methods.


Subject(s)
Biosensing Techniques/instrumentation , Immunoassay/methods , Influenza A Virus, H1N1 Subtype , Influenza B virus , Influenza, Human/diagnosis , Quartz , Animals , Antibodies, Viral , Cell Line , Crystallization , DNA, Viral/analysis , DNA, Viral/genetics , Gold/chemistry , Humans , Influenza A Virus, H1N1 Subtype/genetics , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza A Virus, H1N1 Subtype/physiology , Influenza A Virus, H3N2 Subtype/genetics , Influenza A Virus, H3N2 Subtype/immunology , Influenza A Virus, H3N2 Subtype/isolation & purification , Influenza A Virus, H3N2 Subtype/physiology , Influenza B virus/genetics , Influenza B virus/immunology , Influenza B virus/isolation & purification , Influenza B virus/physiology , Influenza, Human/virology , Micro-Electrical-Mechanical Systems , Reagent Kits, Diagnostic , Sensitivity and Specificity , Virus Cultivation
8.
Drugs ; 68(11): 1483-91, 2008.
Article in English | MEDLINE | ID: mdl-18627206

ABSTRACT

Human vaccines against influenza have been available for almost 60 years and, until recently, were prepared almost entirely from viruses grown in the allantoic cavity of 9- to 11-day-old embryonated chicken eggs. Manufacture involving eggs is not sufficiently flexible to allow vaccine supplies to be rapidly expanded, especially in the face of an impending pandemic. Other problems may arise from the infections of progenitor flocks that adversely affect egg supplies, and from the manufacturing process itself, where breakdowns in sterility can occur from the occasional contamination of large batches of viral allantoic fluid. In addition, egg-grown viruses exhibit differences in antigenicity from viruses isolated in mammalian cell lines from clinical specimens. These concerns and the probable need for greatly expanded manufacturing capability in the future have been brought into focus in recent years by the limited spread of H5N1 avian influenza infections to humans in several Asian countries. Alternative approaches involving the use of accredited anchorage-dependent and -independent preparations of the African Green monkey kidney (Vero), Madin-Darby canine kidney (MDCK) and other cell lines have been pursued by several manufacturers in recent years. Yields comparable with those obtained in embryonated eggs have been achieved. These improvements have occurred in parallel with newer technologies that allow the growth of cells in newer synthetic media that do not contain animal serum, in order to allay the concerns of regulators about the potential for spread of transmissible spongiform encephalopathies.


Subject(s)
Influenza Vaccines , Influenza, Human , Animals , Cells, Cultured , Disease Outbreaks , Humans , Influenza A virus/immunology , Influenza A virus/isolation & purification , Influenza B virus/immunology , Influenza B virus/isolation & purification , Influenza Vaccines/economics , Influenza, Human/epidemiology , Influenza, Human/immunology , Influenza, Human/prevention & control , Vaccines, Synthetic/economics
9.
J Virol Methods ; 147(2): 312-8, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17976832

ABSTRACT

A real-time PCR was used to measure increases in viral DNA in Marek's disease virus (MDV)-infected primary chicken cell cultures in order to optimize methods for viral isolation. Serotype-1 and -3 vaccine and serotype-1 challenge strains exhibited similar growth characteristics, with increases in viral DNA being proportional to inoculum size. Studies of viral growth revealed a linear relationship between increase in MDV copy number and infectious titre, although the rate of increase for copy number was greater. Using real-time PCR, viral DNA yields of the virulent Woodlands strain in infected chicken kidney cultures were shown to be slightly, but not significantly, higher than in chicken embryo kidney cultures and significantly higher than in chicken embryo fibroblast cultures. Viral DNA levels in freshly trypsinised cells suspended in growth medium and infected with the Woodlands strain were higher than levels obtained following the inoculation of monolayer cultures. For cells infected in suspension, no significant enhancement of yield was observed following a medium change after 2-3 days. Peak yields were obtained at days 6-8 after inoculation of all cultures. Findings obtained from the optimization of viral DNA levels were applied to a program for the isolation of Australian strains of serotype-1 viruses from problem flocks over 3 years. Significant improvements were obtained in the isolation rate of strains capable of growing to high titre (>10(4) plaque-forming units/mL) for use in challenge studies.


Subject(s)
Chickens/virology , Herpesvirus 2, Gallid/isolation & purification , Marek Disease/virology , Reverse Transcriptase Polymerase Chain Reaction/methods , Animals , Cells, Cultured , DNA, Viral/isolation & purification , Herpesvirus 2, Gallid/growth & development
10.
Avian Pathol ; 36(5): 351-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17899458

ABSTRACT

A real-time quantitative polymerase chain reaction was utilized to study the in vivo replication of Marek's disease vaccine viruses and of virulent oncogenic strains. In the first of four experiments, the growth of the herpes virus of turkeys (HVT) vaccine was detectable in various organs of infected chicken embryos, with the highest viral loads being present in the spleen. No evidence was obtained for replication of serotype-1 Marek's disease viruses in embryos. In the second experiment, viral loads were measured in several organs of chickens after administration of the Rispens and HVT vaccines immediately after hatching. Lowest levels were noted for the Rispens strain after 1 to 8 weeks. By contrast, HVT vaccine grew well in all tested organs, with the highest loads being present in the spleen. Highest loads were observed in unvaccinated birds after challenge with the highly virulent strain MPF57 at day 8, especially in lymphoid organs. A positive relationship was observed between viral load and clinical signs, including tumour formation. In a third study, viral loads were measured in the organs of chickens administered the Rispens vaccine on the day of hatch and challenged at day 8 with MPF57. High levels of clinical protection were afforded against MPF57 by the Rispens vaccine but, in confirmation of earlier findings, sterilizing immunity was not induced. In a fourth study, two experiments were conducted--in which viral loads were measured after challenge of chickens vaccinated with HVT in ovo or at day 1 after hatching. Similar protection was achieved in birds vaccinated in ovo on embryonic days 11 and 17, although protection was slightly, but not significantly, lower than for birds vaccinated at day 1.


Subject(s)
Mardivirus/immunology , Marek Disease Vaccines/immunology , Marek Disease/immunology , Marek Disease/prevention & control , Animals , Brain/virology , Bursa of Fabricius/virology , Chick Embryo , Drug Administration Routes , Liver/virology , Lung/virology , Marek Disease Vaccines/administration & dosage , Polymerase Chain Reaction/veterinary , Specific Pathogen-Free Organisms , Spleen/virology , Thymus Gland/virology , Viral Load
11.
Vaccine ; 23(31): 4075-81, 2005 Jul 01.
Article in English | MEDLINE | ID: mdl-15963362

ABSTRACT

We previously described differences in the 50% protective dose and isotype-specific antibody secreting cell (ASC) responses to US and Russian influenza A cold-adapted (ca) donor strains in the lungs of BALB/c mice [Wareing MD, Watson JM, Brooks MJ, Tannock GA. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza A vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol 2001;65(1):171-7]. A/Leningrad/134/17/57(Len/17-ca) was shown to be a superior immunogen to A/Leningrad/134/47/57-ca (Len/47-ca), which, in turn, was superior to A/Ann Arbor/6/60-ca (AA-ca) but no other comparative data exist. In order to extend our findings and determine a means for selecting the most immunogenic ca influenza A vaccine, the intracellular cytokine responses by CD4+ and CD8+ T cells to AA-ca, Len/47-ca and Len/17-ca and their respective wild-type parental viruses were compared in mice. Day 5 after infection with Len/17-ca, when levels of IL-2, -4 and -10 were highest in the mediastinal lymph nodes (MLN) and lungs, was chosen as the optimum time to harvest lymphocytes and 72 h was determined to be the optimum re-stimulation period for lymphocytes by APCs. Under these conditions, the frequency of CD4+ and CD8+ cells expressing cytokines was highest in the lungs compared with the MLN. A dominant IL-6 response was induced, although all virus strains induced a Th1/Th2 cytokine profile. While the CD8+ cytokine response appeared non-specific, the cytokine response elicited in the lungs by CD4+ cells to Len/17-ca-inoculation was greater than that induced by Len/47-ca, or AA/ca. The CD4+ cytokine response in the lungs may be a useful measure of immunogenicity to determine the most effective influenza reassortant for inclusion in vaccines.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Cytokines/analysis , Influenza A virus/immunology , Influenza Vaccines/immunology , Lung/immunology , Orthomyxoviridae Infections/prevention & control , Animals , CD8-Positive T-Lymphocytes/immunology , Cold Temperature , Lymph Nodes/immunology , Male , Mice , Mice, Inbred BALB C , Species Specificity
12.
J Gen Virol ; 86(Pt 5): 1327-1333, 2005 May.
Article in English | MEDLINE | ID: mdl-15831943

ABSTRACT

The pathogenesis of strain 3711 of the chicken anemia virus (CAV), propagated in chickens, and two preparations of strain 3711 that had been adapted to grow to high titre in cells of the MDCC-MSB1 line were studied in chicken embryos and/or chickens. Highest viral loads in infected chickens, as measured by a microplate DNA-hybridization assay, were detected in the thymus, clotted blood and pancreas, and the lowest in the duodenum. The CAV DNA copy number in the organs of chicken embryos was significantly lower than in chickens. Route of infection was an important determinant of the course of disease in chickens, with clinical signs appearing earlier in birds infected by the intramuscular than those infected by the oral route; there was a direct relationship between viral load in particular organs and the extent of clinical signs. No reduction in the pathogenicity for chickens was noted for strain 3711 after 65 or 129 passages in the MDCC-MSB1 cell line.


Subject(s)
Chicken anemia virus/growth & development , Circoviridae Infections/veterinary , Poultry Diseases/virology , Viral Load , Animals , Blood/virology , Body Weight , Chick Embryo , Chickens , Circoviridae Infections/virology , DNA, Viral/analysis , DNA, Viral/isolation & purification , Duodenum/virology , Nucleic Acid Hybridization , Pancreas/virology , Thymus Gland/virology
14.
Curr Opin Pulm Med ; 10(3): 197-203, 2004 May.
Article in English | MEDLINE | ID: mdl-15071371

ABSTRACT

PURPOSE OF REVIEW: The emergence of severe acute respiratory syndrome in late 2002 and the recent outbreaks of avian influenza in Asia are timely reminders of the ever present risks from respiratory viral diseases. Apart from influenza, there are no vaccines and very few antiviral chemotherapeutic agents available for the prevention and treatment of respiratory viral infections-the most common cause of human illness. If the current H5N1 avian influenza outbreak ever assumes the role of a pandemic, formidable technical difficulties relating to the properties of the agent, itself, will ensure that vaccines will only become available after a significant lead time and then only to a relatively small percentage of the population. The use of existing antivirals could be critical in limiting the initial spread of a pandemic, although their use in the control of epidemics caused by nonpandemic viruses has not been evaluated. It is against this background that a review of recent developments in respiratory antivirals has been undertaken. RECENT FINDINGS: The late 1990s were a period of unprecedented activity in the development of new and much superior antivirals for the treatment of influenza infections. However, during the past 2 to 3 years and largely for commercial reasons, there has been a decline in interest in their further development by major drug companies. This situation may soon change with the possible advent of new pandemic viruses, and moves are afoot in several countries to consider the stockpiling of antivirals. The neuraminidase inhibitors zanamivir and oseltamivir, and the M2 inhibitors amantadine and rimantadine, remain the only options for controlling respiratory disease caused by influenza viruses, although the latter two could not be used against very recent H5N1 strains. There are several other neuraminidase inhibitors in development. Compounds with activity against other respiratory viruses, notably rhinoviruses, are also in development, many based on a newer knowledge of viral protein structure and function (rational drug design). SUMMARY: The following is an overview of recent papers on the further development of neuraminidase inhibitors against influenza viruses and on recent development of newer antivirals against RSV and rhinoviruses. Where possible, comparisons are made with existing antivirals. For considerations of space, this review has been structured around stages in the replication cycle of significant respiratory viruses that have been traditionally used as targets for inhibition.


Subject(s)
Antiviral Agents/therapeutic use , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/virology , Virus Diseases/drug therapy , Antiviral Agents/pharmacology , Drugs, Investigational/pharmacology , Drugs, Investigational/therapeutic use , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Ion Channels/antagonists & inhibitors
15.
Curr Opin Pulm Med ; 8(3): 209-13, 2002 May.
Article in English | MEDLINE | ID: mdl-11981310

ABSTRACT

Although influenza activity throughout the world has been relatively low during the past year, epidemics of influenza A, in particular, which are caused by new virus variants, continue to be a major public health problem. Widespread vaccination is the only rational measure that can be used for the prevention of illness in key risk groups. Although current inactivated split/subunit vaccines are reasonably effective, significant improvements have been shown to be possible in the boosting of responses by the use of particular adjuvants and/or the direct administration of vaccines to the respiratory tract. Live attenuated vaccines, also administered directly to the respiratory tract, have continued to be shown to be safe and effective, and, in the longer term, probably will have a major role in influenza prophylaxis, especially in children and young adults.


Subject(s)
Influenza Vaccines , Influenza, Human/prevention & control , Clinical Trials as Topic , Drug Design , Humans , Influenza A virus/immunology , Influenza B virus/immunology , Influenza Vaccines/biosynthesis , Influenza, Human/epidemiology , Vaccines, Attenuated , Vaccines, DNA , Vaccines, Inactivated
SELECTION OF CITATIONS
SEARCH DETAIL
...